Abstract | BACKGROUND: METHODS: RESULTS: The overall risk of death (hazard ratio, 1.03; 95% confidence interval [CI], 0.80 to 1.30) and the combined risk of death or myocardial infarction (hazard ratio, 0.97; 95% CI, 0.81 to 1.16) were not significantly different for patients receiving sirolimus-eluting stents versus bare- metal stents. There was a significant reduction in the combined risk of death, myocardial infarction, or reintervention (hazard ratio, 0.43; 95% CI, 0.34 to 0.54) associated with the use of sirolimus-eluting stents. There was no significant difference in the overall risk of stent thrombosis with sirolimus-eluting stents versus bare- metal stents (hazard ratio, 1.09; 95% CI, 0.64 to 1.86). However, there was evidence of a slight increase in the risk of stent thrombosis associated with sirolimus-eluting stents after the first year. CONCLUSIONS:
|
Authors | Adnan Kastrati, Julinda Mehilli, Jürgen Pache, Christoph Kaiser, Marco Valgimigli, Henning Kelbaek, Maurizio Menichelli, Manel Sabaté, Maarten J Suttorp, Dietrich Baumgart, Melchior Seyfarth, Matthias E Pfisterer, Albert Schömig |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 356
Issue 10
Pg. 1030-9
(Mar 08 2007)
ISSN: 1533-4406 [Electronic] United States |
PMID | 17296823
(Publication Type: Comparative Study, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2007 Massachusetts Medical Society. |
Chemical References |
- Immunosuppressive Agents
- Sirolimus
|
Topics |
- Angioplasty, Balloon, Coronary
- Coronary Disease
(mortality, therapy)
- Coronary Restenosis
(epidemiology, therapy)
- Coronary Thrombosis
(epidemiology, etiology)
- Drug Delivery Systems
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(administration & dosage)
- Myocardial Infarction
(epidemiology, etiology)
- Prosthesis Design
- Prosthesis Failure
- Randomized Controlled Trials as Topic
- Regression Analysis
- Risk
- Sirolimus
(administration & dosage)
- Stents
(adverse effects)
- Survival Analysis
|